CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

Data Supplement

Four figures and one table; one PDF file.

Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2016 American Academy of Neurology.

Files in this Data Supplement:

• Figures e-1 to e-4, Table e-1 - PDF file